Women's Health

Latest News


CME Content


Approved by the FDA on April 9, 2019, Amgen’s romosozumab-aqqg therapy (Evenity) is indicated for osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Many women are unaware of HIV pre-exposure prophylaxis (PrEP) but show a keen interest in spreading the word once they learn about the option, according a recent study in the journal Contraception.